Journal of Pediatric Hematology-Oncology Nursing最新文献

{"title":"Challenges of Treatment Decisions for Children With Hematological Malignancies Who Relapse After Hematopoietic Stem Cell Transplant: A Health Care Provider Perspective.","authors":"Deborah Tomlinson, Sonia Lucchetta, Sarah Alexander, Sumit Gupta, Erilda Kapllani, Tal Schechter-Finkelstein, Jane Lowry, Joerg Krueger","doi":"10.1177/27527530261448471","DOIUrl":"https://doi.org/10.1177/27527530261448471","url":null,"abstract":"<p><p>BackgroundWhen a child or adolescent's disease relapses following hematopoietic stem cell transplantation (HSCT), families are often presented with the complex decision to pursue further treatment with curative intent. This study aims to describe the experiences of health care professionals (HCPs) regarding choices after the first HSCT and factors influencing decision-making.MethodThis qualitative study included staff and trainee physicians, nurse practitioners, and nurse coordinators. All participants had experience caring for children who had received HSCT. Sampling was purposive. We applied a descriptive phenomenological study design using semistructured interviews. Interviews were recorded and transcribed. Two researchers analyzed and coded transcript data. Themes and subthemes were identified. Ranking and scoring of the importance of factors, using a visual analogue scale (VAS) ranging from 0 to 10, that could influence decision-making were examined.ResultsA total of 32 HCPs participated. We identified four themes: (a) navigating self; (b) factors affecting decisions; (c) child and family support; and (d) decision-making biases. There were 12 subthemes. When ranking importance in a list of nine factors, higher ranking was associated with chance of cure, child's quality of life, and the child's preference of treatment. Importance scoring for these three factors plus risks of severe short- and long-term health issues received the highest scores (VAS 9 or 10).DiscussionProviding treatment with curative intent and involving the child in decision-making were important to HCPs. Chance of cure, child preference, quality of life, and risks of health issues were important factors. HCPs should consider the introduction of a palliative care team and discuss the chance of cure.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"27527530261448471"},"PeriodicalIF":1.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148832918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diet, Gastrointestinal Symptoms, and Health-Related Quality of Life in Children With Solid Tumors Receiving Chemotherapy.","authors":"Avery Giffen, Caitlin I Webster, Melissa Martin, Kathryn S Sutton, Thomas Olson, Hye In Noh, Deborah Watkins Bruner, Jinbing Bai","doi":"10.1177/27527530261462150","DOIUrl":"10.1177/27527530261462150","url":null,"abstract":"<p><p>BackgroundChildren undergoing chemotherapy often experience gastrointestinal (GI) symptoms, negatively impacting health-related quality of life (HRQOL). Although macro- and micronutrients have been associated with GI symptoms and HRQOL following cancer diagnosis, more evidence is needed in pediatric oncology populations. This study examines how dietary intake is associated with GI symptoms and HRQOL in children with solid tumors undergoing chemotherapy.MethodThis secondary analysis used the Block Kids Food Screener to assess intake of macro- and micronutrients; the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to measure GI symptoms; and the PedsQL 4.0 to evaluate HRQOL. Logistic and adjusted linear regression models were used to examine how dietary intake was associated with GI symptoms and HRQOL.ResultsThis study included 57 children with a mean age of 13.8 years (<i>SD</i> = 3.5). The majority were male (64.9%) and non-Hispanic White (43.9%). Increased vitamin C was associated with reduced nausea, while increased carbohydrates and beta-carotene were correlated with reduced diarrhea and increased vitamin E with reduced constipation. Increased total fat increased the odds of diarrhea. Higher protein and selenium and lower carbohydrates and vitamin C were associated with better physical HRQOL. A positive association between vitamin A and social HRQOL was noted.ConclusionHigher intakes of carbohydrates, beta-carotene, vitamin C, and vitamin E and lower intake of fat were associated with fewer GI symptoms, while greater consumption of protein, selenium, and vitamin A and lower carbohydrates were linked to improved HRQOL. Findings provide preliminary evidence for development of nutritional plans for pediatric patients undergoing chemotherapy.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"27527530261462150"},"PeriodicalIF":1.6,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Nurse Acceptability of Dexmedetomidine Use During I-131 MIBG Therapy in Pediatric Patients With Neuroblastoma.","authors":"Jennifer Spidle, Jean C Solodiuk, Megan Lurvey, Alexis Day, Elaine Lambrinos, Jennifer Costa","doi":"10.1177/27527530261424227","DOIUrl":"10.1177/27527530261424227","url":null,"abstract":"<p><p>BackgroundI-131 metaiodobenzylguanidine (MIBG) therapy effectively treats high-risk neuroblastoma but exposes caregivers and healthcare providers to radiation risks. Managing patient anxiety and agitation is essential for safety. Dexmedetomidine has shown potential as an anxiolytic, but its feasibility and acceptability in this setting are underexplored. This quality improvement (QI) project aimed to evaluate the feasibility and nurse acceptability of dexmedetomidine anxiolysis in our patient population.MethodA retrospective chart review was conducted for pediatric patients who received dexmedetomidine during MIBG therapy between January and June 2023. Feasibility was assessed through adverse events, vital sign changes, and dose adjustments. Nurse acceptability was evaluated using a questionnaire adapted from the Theoretical Framework of Acceptability and a follow-up focus group.ResultsSeven patients received the full MIBG dose with dexmedetomidine and experienced no adverse events. Minor, transient vital sign changes were noted, and all patients adhered to radiation safety protocols. Ten nurses completed the acceptability questionnaire; 100% reported that dexmedetomidine was easy to administer, promoted patient safety, and supported safe MIBG administration. Ninety percent found dexmedetomidine to be an acceptable anxiolytic. Focus group participants (<i>n</i> = 3) identified themes surrounding intravenous access challenges and the need for improved interdisciplinary communication.DiscussionDexmedetomidine appeared to be a feasible and acceptable anxiolytic for pediatric patients receiving MIBG therapy in this small, single-unit QI project. Practice changes included a preadmission multidisciplinary huddle, interdisciplinary huddle requests for clinical concerns, and a dexmedetomidine administration standard operating procedure. This project underscores the importance of multidisciplinary collaboration and nurse feedback in refining clinical practice.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"258-268"},"PeriodicalIF":1.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the Shadows of Stigma in Sickle Cell Disease: A Phenomenological Study.","authors":"Abby O Seydel, Mary J Isaacson, Brandon M Varilek","doi":"10.1177/27527530261424176","DOIUrl":"10.1177/27527530261424176","url":null,"abstract":"<p><p>BackgroundThe purpose of this study was to explore the experience of stigma among young adults living with sickle cell disease (SCD) using a hermeneutic phenomenological design.MethodSeven young adults diagnosed with SCD participated in semi-structured interviews to explore their experience of stigma as young adults living with SCD. Interviews were transcribed verbatim and analyzed using interpretive phenomenology.ResultsThe participants' narratives revealed an overarching theme of <i>the shadows,</i> representing their experience with stigma. The three subthemes further define how they navigate the shadow of stigma and move through varying degrees of dark and light to balance authenticity and protection. Subthemes include (a) the umbra-darkness, (b) the penumbra-dark and light collide, and (c) the antumbra-light.DiscussionThis study reveals the complex realities of young adults with SCD as they navigate stigma. Each narrative reinforced how stigma is ever-present in their experiences in healthcare, the public, and among family and friends. This research can help health professionals understand the influence stigma has on how young adults with SCD perceive themselves, interact with others, and engage in health-seeking behaviors and highlights the need to address stigma as a structural barrier to health equity.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"205-215"},"PeriodicalIF":1.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Storytelling on Anxiety Level of Children With Cancer: One-Group Pretest-Posttest Study.","authors":"Merve Kurt, Tuba Arpaci","doi":"10.1177/27527530261448508","DOIUrl":"10.1177/27527530261448508","url":null,"abstract":"<p><p>BackgroundThis one-group pretest-posttest experimental research was conducted to determine the effect of storytelling on the anxiety levels of children diagnosed with cancer.MethodChildren aged 4-10 years and their parents in the pediatric hematology-oncology service of a university hospital were included in the study (<i>N</i> = 39). A 2-day storytelling intervention with the <i>A Hopeful Cloud Story</i> book to help children express their anxieties and cope with the changes caused by hospitalization for cancer treatment was applied to children. The Child Fear Scale (CFS) was used to evaluate the anxiety levels of children before and after the intervention.ResultsThe average age of the children was <i>M</i> (<i>SD</i>) = 6.54 (2.11) years, and most were male (56.4%). According to the children's reports, the CFS pretest mean score was <i>M</i> (<i>SD</i>) = 3.54 (0.55), and the posttest mean score was <i>M</i> (<i>SD</i>) = 1.33 (0.48). In the posttest, it was determined that the children's CFS scores decreased (<i>p</i> < .001). According to parent and researcher reports, a significant decrease was observed in the children's CFS scores after the intervention.DiscussionAs a result, the storytelling intervention is effective in reducing children's anxiety levels. It would be helpful to use a storytelling intervention in the treatment and care processes of children with cancer.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"216-223"},"PeriodicalIF":1.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication Adherence in Pediatric Sickle Cell Disease and Hematopoietic Stem Cell Transplantation: An Integrative Review of Literature.","authors":"Misty Evans, Samereh Abdoli, Micah Skeens, Dominique Bulgin, Lisa C Lindley","doi":"10.1177/27527530261448518","DOIUrl":"10.1177/27527530261448518","url":null,"abstract":"<p><p>BackgroundWith the emergence of haploidentical transplantation, children with sickle cell disease (SCD) are increasingly pursuing hematopoietic stem cell transplantation (HSCT) as a curative treatment approach. However, suboptimal medication adherence remains a persistent challenge in both SCD and HSCT populations. Adherence to complex medication regimens is crucial to reducing the risk of severe complications and early mortality, yet no synthesis has evaluated patterns of adherence among patients with SCD post-HSCT.MethodWe conducted an integrative review, searching PubMed, CINAHL, and PsycINFO from April 2025 to May 2025 for studies measuring medication adherence in children (≤21 years) with SCD and/or HSCT. Studies were included if they reported adherence rates and excluded if they involved adherence interventions or drug development trials.ResultsEighteen studies met inclusion criteria: 12 addressed SCD and 6 focused on HSCT. No studies specifically examined adherence in patients with SCD post-HSCT. Adherence rates to disease-modifying medications in SCD ranged from 10% to 89%, while post-HSCT adherence ranged from 40% to 73%. Nonadherence was associated with increased complications across both populations.DiscussionThese findings highlight a critical research gap and provide a foundation for targeted adherence interventions. Addressing this gap is essential to advance nursing practice, improve adherence, and optimize clinical outcomes in pediatric hematology and HSCT care.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"245-257"},"PeriodicalIF":1.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predisposing, Precipitating, Perpetuating, and Protective Factors Associated With Distress in the Siblings of Children With Cancer: A Systematic Review.","authors":"Isabella Zaffino, Mackenzie Murawsky, Dawn Stacey, Gail Macartney, Elham Hashemi, Christina Di Carlo, Lindsey Sikora, Lauren Mulrooney, Maria Gladkikh, Victoria Sanderson, Kyobin Hwang, Sasha Mazzarello, Maya Bristoll, Michaela Beaudry, Lindsay Jibb","doi":"10.1177/27527530261448461","DOIUrl":"https://doi.org/10.1177/27527530261448461","url":null,"abstract":"<p><p>BackgroundSiblings in families caring for a child with cancer have unique childhood experiences, often resulting in high levels of anxiety, depression, and posttraumatic stress symptoms.ObjectiveThis systematic review aims to summarize and categorize factors related to increased and decreased experiences of emotional distress among siblings of children with cancer.MethodUsing the Cochrane method, searches were conducted in six academic databases. Eligible studies included those examining siblings of children with cancer aged 21 years old or younger and on active treatment and reported on factors associated with sibling experiences of distress. Identified factors were categorized in accordance with the 4Ps of case formulation (predisposing, precipitating, perpetuating, and protective factors). Results were reported using a narrative synthesis.ResultsOf 18,059 studies retrieved, we included 12 articles. In total, 19 factors were identified, including 7 predisposing factors (e.g., sibling age), 1 precipitating factor (sibling perception of threat to lifestyle), 8 perpetuating factors (e.g., increased caregiving burden), and 3 protective factors (e.g., greater time elapsed since diagnosis). Predisposing, precipitating, and perpetuating factors increased sibling distress, while protective factors reduced sibling distress.ConclusionWe identified factors associated with distress in siblings of children with cancer. The findings may enable clinicians to identify siblings at greater risk of experiencing distress and inform the creation of psychosocial interventions that decrease experiences of distress in siblings.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":"43 4","pages":"224-235"},"PeriodicalIF":1.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148832921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening of Cognitive Symptoms During Treatment for Childhood Leukemia Predicts Post-Treatment Cognitive Functioning.","authors":"Alyssa Krentzel, Joan Yu, Olga A Taylor, Chi-Fan Lin, Emily Mason, Marilyn Hockenberry, Michael E Scheurer, Austin L Brown, Kimberly P Raghubar","doi":"10.1177/27527530261448462","DOIUrl":"10.1177/27527530261448462","url":null,"abstract":"<p><p>BackgroundThe current study describes the trajectory of caregiver-reported cognitive functioning for children treated for acute lymphoblastic leukemia (ALL) and correlations with post-treatment caregiver-reported and performance-based cognitive functioning.MethodThe PROMIS parent proxy cognitive function questionnaire was collected at four time points during childhood ALL treatment for 40 participants who also completed post-treatment PROMIS parent proxy reports and neurocognitive evaluations.ResultsPatients (52.5% male) were diagnosed with standard (45.0%) or high-risk B-ALL (47.5%) at a mean age of 7.80 years. During the first year of treatment, caregiver reports revealed a statistically significant (<i>p</i> < .01) decline in child cognitive functioning of 0.37 <i>SD</i> (95% CI: [0.12-0.62]) evaluated using mixed-effects linear regression. Caregiver report of cognitive functioning at the end of the first year of treatment correlated with post-treatment ratings (<i>p</i> < .05), after accounting for demographic and clinical factors. Post-treatment caregiver-reported cognitive functioning was significantly associated with estimated IQ (<i>p</i> < .01), attention (<i>p</i> < .05), word reading (<i>p</i> < .05), and calculation (<i>p</i> < .01).DiscussionTreatment for childhood ALL results in subtle changes in caregiver perception of cognitive functioning that are detectable shortly after diagnosis and may persist into survivorship. Furthermore, this study presents preliminary evidence for use of the PROMIS parent proxy cognitive function questionnaire as a screener for cognitive difficulties that may require further neurocognitive monitoring or comprehensive evaluation.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"236-244"},"PeriodicalIF":1.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Concerns on Access to Supportive Care Medicines and Symptom Management Outcomes Among Children with Cancer in Tanzania.","authors":"Deogratias M Katabalo, Jacquline Chuwa, Stanley Mwita, Antony H Liwa, Benson R Kidenya, Kristin Schroeder","doi":"10.1177/27527530251398467","DOIUrl":"10.1177/27527530251398467","url":null,"abstract":"<p><p>BackgroundPediatric cancers cause significant morbidity and mortality among children in Tanzania. Chemotherapy remains the primary treatment, but it often leads to treatment-induced toxicities that necessitate supportive care medicines. This study assessed patient-reported concerns about access to supportive medicines and evaluated symptom management outcomes among children with cancer at a major referral hospital.MethodWe conducted a descriptive cross-sectional study over 6 months among children with cancer receiving chemotherapy at Bugando Medical Centre. Data on access to and utilization of supportive care medicines and symptom relief were collected through a semi-structured questionnaire, cleaned in Microsoft Excel 2019, and analyzed with STATA Version 15.ResultsAmong 120 participants (61 female, 59 male), access to supportive care medicines was poor for 68.33%. Utilization was high at 99.17%. Most patients (62.50%) reported good symptom resolution after using supportive care medicines, whereas 37.50% continued to experience disruptions to daily activities due to chemotherapy-induced toxicities.DiscussionFinancial difficulties and limited insurance coverage contributed to poor access to supportive medicines. Despite this, utilization was high and associated with symptomatic improvement for most participants. These findings suggest that improved financial support and availability of supportive medicines could enhance symptom-management outcomes for children with cancer in Tanzania.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"170-177"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naxitamab for Relapsed/Refractory Neuroblastoma.","authors":"Teresa Herriage, Jawhar Rawwas, Adam Sterman, Emma Hennen, Erin Bevers","doi":"10.1177/27527530251410910","DOIUrl":"10.1177/27527530251410910","url":null,"abstract":"<p><p>BackgroundChildren with relapsed/refractory (R/R) neuroblastoma are at risk for poor outcomes due to resistant disease. Naxitamab is an anti-glycolipid disialoganglioside (GD2) monoclonal antibody approved by the Food and Drug Administration for the treatment of R/R high-risk neuroblastoma. Serious adverse reactions are an expected part of treatment and include severe nerve pain during the infusion. Institutions using an interdisciplinary team approach can create a safe system for the infusion of naxitamab in the outpatient clinic setting. The purpose of this article is to present this immunotherapy, naxitamab, its adverse events (AEs), and one institution's approach in administering naxitamab in an outpatient infusion center.MethodAn interdisciplinary team, led by a pediatric oncology advanced practice nurse, developed a detailed standardized care plan that can be tailored to the patient's previous history with pain medications and response to naxitamab. The team includes multiple nursing roles, physician specialists, pharmacists, psychosocial staff, and the patient and family; each team member is educated in their defined role.ResultsAEs can be effectively managed, and naxitamab infusions can be safely infused in the outpatient infusion center through repeated cycles of treatment. Patients can be discharged to home 2 hr after the completion of the infusion.DiscussionOutpatient administration of naxitamab requires exact planning and implementation by a well-prepared interdisciplinary team. This approach supports patients and families in maximizing their quality of life through ambulatory care.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":" ","pages":"189-197"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}